LOVENOX (PRESERVATIVE FREE) Drug Patent Profile

When do Lovenox (preservative Free) patents expire, and when can generic versions of Lovenox (preservative Free) launch?

Lovenox (preservative Free) is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LOVENOX (PRESERVATIVE FREE) is enoxaparin sodium. There are thirteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the enoxaparin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lovenox (preservative Free)

A generic version of LOVENOX (PRESERVATIVE FREE) was approved as enoxaparin sodium by SANDOZ INC on November 28^th, 2011.

Summary for LOVENOX (PRESERVATIVE FREE)

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	25
DailyMed Link:	LOVENOX (PRESERVATIVE FREE) at DailyMed

Pharmacology for LOVENOX (PRESERVATIVE FREE)

Drug Class

Low Molecular Weight Heparin

Paragraph IV (Patent) Challenges for LOVENOX (PRESERVATIVE FREE)

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LOVENOX (PRESERVATIVE FREE)	Injection	enoxaparin sodium	100 mg/mL, 3 mL vials	020164	1	2006-12-07

US Patents and Regulatory Information for LOVENOX (PRESERVATIVE FREE)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-001	Mar 29, 1993	AP	RX	Yes	No
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-007	Jun 2, 2000	AP	RX	Yes	No
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-004	Mar 27, 1998	AP	RX	Yes	No
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-008	Jun 2, 2000	AP	RX	Yes	No
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-002	Jan 30, 1998	AP	RX	Yes	No

Expired US Patents for LOVENOX (PRESERVATIVE FREE)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-004	Mar 27, 1998	4,692,435
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-003	Mar 27, 1998	RE38743
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-002	Jan 30, 1998	4,692,435
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-005	Mar 27, 1998	4,692,435
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-007	Jun 2, 2000	4,692,435

EU/EMA Drug Approvals for LOVENOX (PRESERVATIVE FREE)

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Techdow Pharma Netherlands B.V.	Inhixa	enoxaparin sodium	EMEA/H/C/004264Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis.	Authorised	no	yes	no	2016-09-15
Pharmathen S.A.	Thorinane	enoxaparin sodium	EMEA/H/C/003795Thorinane is indicated for adults for:, , - Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery., , - Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL)., , - Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism., , - Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA)., , - Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL)., , - Blood clot prevention in the extracorporeal circulation during haemodialysis., , Prevention and treatment of various disorders related to blood clots in adults.,	Withdrawn	no	yes	no	2016-09-14

International Patents for LOVENOX (PRESERVATIVE FREE)

See the table below for patents covering LOVENOX (PRESERVATIVE FREE) around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	227417	PROCEDIMIENTO PARA LA OBTENCION DE MUCOPOLISACARIDOS QUE POSEEN ACTIVIDAD ANTI-XA(YIN-WESSLER)ELEVADA,CON UNA RELACION DE SU TITULO YIN-WISSLER A SU TITULO USP DE AL MENOS IGUAL A 2
Austria	17586
Austria	26450
Australia	540433
Australia	543679

LOVENOX (PRESERVATIVE FREE) Market Dynamics and Financial Trajectory: Key Drivers, Pricing, Competition, and Revenue Outlook

Last updated: July 26, 2026

LOVENOX (enoxaparin sodium) preservative free targets anticoagulation use in inpatient and specialty settings where clinicians value low-irritant, ready-to-administer formulations. Over time, the product’s financial trajectory is shaped by (1) generic and biosimilar-like substitution pressure from low-molecular-weight heparin (LMWH) competitors, (2) tender and formulary dynamics for hospital procurement, (3) payer constraints tied to dosing economics, (4) portfolio and manufacturing actions after product continuity events, and (5) whether anticoagulation patterns shift toward alternative regimens or agent classes. The market has also been affected by patent-expiration cycles and the availability of branded versus generic LMWH products in specific package types, including preservative-free presentations.

---

What is LOVENOX (preservative free) used for, and how do those indications shape demand?

Quick answer: LOVENOX (preservative free) demand is concentrated in guideline-driven anticoagulation indications, with utilization skewed toward hospital inpatient flows and peri-procedural prophylaxis, where clinicians maintain consistent dosing protocols.

Which clinical indications drive utilization

LOVENOX (enoxaparin sodium) is prescribed across multiple anticoagulation settings, typically including:

• VTE prophylaxis in medical and surgical patients
• Treatment of DVT/PE and related indications
• ACS and other cardiovascular anticoagulation uses
• Peri-procedural anticoagulation management

Demand sensitivity: Hospital formularies often prioritize products that can be used across protocols with consistent dosing and minimal administration friction. That pushes preservative-free presentations into a narrower but durable band of use cases where the formulation is preferred.

Why “preservative free” matters commercially

Commercially, preservative-free versions typically perform best where:

• clinicians substitute by site preference, not only by molecule
• patient administration and line management protocols reduce the perceived risk of irritants
• pharmacy departments prefer standardized administration workflows
• pediatric, oncology, and other specialty services request formulation consistency

This doesn’t eliminate substitution by active ingredient, but it can slow switching within a facility.

---

What market dynamics influence LOVENOX (preservative free) pricing and gross margin?

Quick answer: The biggest pricing levers are hospital contracting, government and commercial payer reimbursement policy, and competitive entry of enoxaparin and LMWH alternatives in the same dose/packaging formats.

Hospital tendering and contract pharmacy pressure

LMWH procurement is typically characterized by:

• reverse-auction or best-price contracting
• multi-source acceptance once guidance and clinical equivalence are established
• formulary switching when price gaps exceed pharmacy thresholds

Even if preservative-free is valued, tender frameworks can force at-risk volume into the lowest-cost acceptable SKU.

Trade-down and package-specific substitution

Within the same molecule category, pricing risk is often driven by:

• availability of lower-cost generic enoxaparin in comparable presentations
• whether a facility can substitute preservative-free versus multi-dose or other variants
• whether procurement contracts specify preservative-free as a condition

When contracts don’t preserve the formulation, volume can move quickly.

Channel mix

Financial performance typically depends on:

• inpatient hospital mix versus outpatient administration
• government program penetration (Medicare/Medicaid) versus commercial plans
• specialty pharmacy share, if used in the setting for ongoing anticoagulation

---

How does competition in LMWH affect LOVENOX (preservative free) revenue trajectory?

Quick answer: Competitive pressure usually comes from generic enoxaparin sodium and other LMWH products, with switching accelerating after key exclusivity windows and as procurement multi-sources the molecule.

Competitive forces at work

1. Generic enoxaparin entry
   Once generic enoxaparin is commercially established, branded volume faces sustained trade-down and price compression. Preservative-free may remain in limited use, but branded market share trends down over time in many geographies.

2. Alternative anticoagulation strategies
   Over longer horizons, some VTE and ACS patients may shift toward other anticoagulant classes. That matters most where payer coverage and clinical protocols support non-LMWH regimens.

3. Formulation-driven retention
   Preservative-free can provide localized retention, especially where administration protocols are strict. That creates a slower decline curve than would be expected for an undifferentiated branded SKU, but it does not fully prevent erosion.

Where the brand retains leverage

LOVENOX retains pricing and volume leverage when:

• hospitals and health systems require preservative-free for protocol compliance
• ordering systems make the preservative-free SKU the default
• clinicians have strong preferences linked to administration practice

---

When does LOVENOX (preservative free) lose exclusivity, and what does that mean for generic entry risk?

Quick answer: Exclusivity timelines determine first-wave generic pressure; the preservative-free variant’s competitive impact then depends on whether generics launch with matching presentations and whether hospitals accept substitution.

Exclusivity vs. market substitution

For a branded LMWH, two effects typically occur around patent and exclusivity milestones:

• First-wave entry: generics appear with aggressive pricing and attempt to capture baseline facility volume.
• Second-wave consolidation: after contracting cycles, multi-source becomes standard, reducing the “premium” branded can command.

Generic entry risk exists for the preserved presentation only if generics launch equivalent preservative-free SKUs in the same dose formats and package sizes that drive contracting decisions.

---

What Paragraph IV ANDA or patent litigation events affect LOVENOX (preservative free)?

Quick answer: Patent litigation risk is most acute in the period immediately before commercial generic entry and settlement outcomes that permit launch timing. For LMWH brands, these events typically drive the pacing of revenue erosion.

How litigation changes the sales curve

Patent settlements and court outcomes influence:

• launch start date for generics
• whether the generic can offer all dose strengths and packaging sizes initially
• whether preservative-free SKUs are covered or excluded in launch plans

In practice, settlement terms often create staggered erosion across strengths, which can slow overall topline decline compared with a single bulk entry.

---

What is the Orange Book status of LOVENOX (preservative free) and which patents cover formulation or method-of-use?

Quick answer: Orange Book coverage for LMWH brands usually includes composition-of-matter and formulation-related patents, plus use-related claims for specific indications. The preservative-free variant can have additional patent lines tied to presentation and manufacturing/formulation.

Patent estate impact on generic design-around

Generic enoxaparin entrants usually focus on:

• establishing equivalence to the active ingredient and dosing
• aligning formulation and manufacturing within allowable patent boundaries
• using carve-outs or sectioning across strengths

Financial linkage: Broader and longer-lived formulation-related patents can keep some dose presentations branded a bit longer, even when the underlying molecule is no longer protected.

(No Orange Book patent list is provided here because the required record-level citations for the specific preservative-free presentation and dose/strength mappings are not included in the prompt.)

---

How do formulation patents for preservative-free enoxaparin differ from standard enoxaparin?

Quick answer: Formulation and manufacturing-method coverage can dictate whether preservative-free SKUs are “fast-follow” replacements or whether they face separate regulatory and patent constraints.

Common formulation patent themes in LMWH

Patent coverage for formulation variants often focuses on:

• excipient composition and manufacturing parameters
• container-closure compatibility
• stability and shelf-life data tied to storage performance
• process controls affecting product characteristics

Commercial effect of formulation differentiation

If preservative-free SKUs have distinct patents or are not directly covered by early generic launches, the brand tends to retain:

• niche but steady replenishment volume
• higher contracting stickiness in select hospital systems
• margin resilience on preservative-free-only tenders

---

What FDA status and labeling dynamics influence LOVENOX (preservative free) uptake?

Quick answer: Uptake is driven by maintained labeling, safety communications, and dosing protocol consistency, which affect hospital adoption and pharmacy stocking behavior.

Label and administration protocols

For anticoagulants, labeling stability affects:

• electronic medical record order sets
• clinical pathway adherence
• pharmacist substitution policies
• payer prior authorization requirements in some settings

Regulatory actions that impact sales

Even when the active ingredient remains unchanged, FDA actions can affect:

• stocking and inventory planning
• distribution continuity
• brand substitution decisions within hospitals

---

What does the competitive landscape look like for preservative-free enoxaparin by product form factor?

Quick answer: Competition is typically product-format specific, since hospital procurement often contracts by vial/syringe presentation, dose strength, and packaging count.

Key format categories

• Pre-filled syringe versus vial presentation
• Dose strengths and concentration
• Pack size relevant to billing and stocking
• Preservative-free versus standard formulations

Financial linkage: If generic alternatives are present in standard formulations but not in preservative-free presentations, the branded preservative-free product can retain a partial share.

---

How does LOVENOX (preservative free) compare with other anticoagulants on market access and cost?

Quick answer: LMWH competes not only with other heparins but also with oral anticoagulants and alternative parenteral agents depending on indication, patient population, and payer coverage.

Cost-per-therapy economics

For buyers, the decision is driven by:

• dosing frequency and administration cost
• facility nursing time and pharmacy handling
• monitoring requirements (where applicable)
• net price after rebates, contracts, and patient assistance

Formulary switching thresholds

Hospitals typically switch when:

• the net price gap favors alternatives
• clinical pathways support the alternative
• perceived administration and adverse-event risk are acceptable

Preservative-free can be a “micro-differentiator” against competing LMWH, but it does not neutralize class-level economics versus non-LMWH agents.

---

What revenue exposure exists for LOVENOX (preservative free) under generic launch scenarios?

Quick answer: Revenue exposure is highest at the moment preservative-free equivalents enter contracts or once multi-source approvals allow substitution without clinical exceptions.

Three launch scenarios that drive outcomes

1. Generic launches with preservative-free equivalents in matching formats
   Fast margin compression; branded volume declines across contracted strengths.

2. Generic launches in non-preservative-free or partial formats
   Slower erosion; brand retains preservative-free-tied accounts.

3. Generic entry faces patent or regulatory bottlenecks for preservative-free SKUs
   Longer tail for the branded preservative-free line; contract renewals may keep the SKU in formularies longer.

---

What manufacturing and supply continuity risks affect financial performance for LOVENOX (preservative free)?

Quick answer: For injectable anticoagulants, supply continuity affects lost sales due to reordering cycles, substitution, and backorder-induced switching.

How supply events change long-term share

Even temporary supply constraints can:

• trigger permanent formulary substitution
• reset contracting terms
• alter clinician and pharmacy “default” ordering in the system

That can create a structural share shift rather than a short-term dip.

---

Key Takeaways

• LOVENOX (preservative free) pricing and revenue trajectory are driven by hospital contracting, package-format specificity, and how quickly multi-source substitution accepts preservative-free SKUs.
• Competitive pressure from generic enoxaparin and class-level anticoagulant alternatives tends to compress branded margins and erode volume over exclusivity and post-litigation windows.
• Formulation-specific patent and launch coverage can preserve a niche but durable share for preservative-free variants when generics do not launch matching presentations immediately.
• Supply continuity and labeling stability affect long-term formulary lock-in, because anticoagulant procurement choices become “system defaults” once substitution occurs.

---

FAQs

1) Does preservative-free enoxaparin prevent substitution by generic enoxaparin?
Not broadly. It can slow switching where hospital protocols and contracts require the preservative-free presentation, but generic equivalents that match formats can still capture volume.

2) Is LOVENOX (preservative free) exposed mainly to patent expiry or to tender-driven price competition?
Both. Patent expiry determines the opening for generic entry, while tenders and contracting decide how fast volume and net price erode after entry.

3) Which product formats matter most for preserving LOVENOX (preservative free) revenue?
Dose strengths, concentration, and pack size tied to hospital purchasing systems. Matching formats between branded and competing SKUs is the key commercial determinant.

4) How do supply disruptions influence longer-term market share?
They can permanently shift ordering defaults and formulary placement, especially in high-throughput inpatient settings with standardized order sets.

5) What are the biggest indicators of future revenue decline for LOVENOX (preservative free)?
Rising multi-source acceptance in hospital contracts, increasing share of generic equivalents in the same preservative-free formats, and continued net price compression in contracted accounts.

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed 2026).